Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of FLUTIFORM [formoterol fumarate/fluticasone propionate] vs Seratide [salmeterol/fluticasone propionate] in paediatric subjects with asthma

Trial Profile

Study of FLUTIFORM [formoterol fumarate/fluticasone propionate] vs Seratide [salmeterol/fluticasone propionate] in paediatric subjects with asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 08 Nov 2018 According to a Mundipharma international media release, based on data from this and other paediatric study, the Mundipharma network of independent associated companies today announced that the European Decentralised Procedure (DCP) licence variation application for flutiform, extending the indication to the treatment of asthmatic children, has closed with a positive opinion.
    • 04 Jul 2012 Company added in the association field as reported by EudraCT.
    • 28 Sep 2011 Extension study tolerability results presented at the 21st Annual Congress of the European Respiratory Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top